Inflammation Research

, Volume 61, Issue 5, pp 401–409

Immune regulation of procalcitonin: a biomarker and mediator of infection

  • G. N. Matwiyoff
  • J. D. Prahl
  • R. J. Miller
  • J. J. Carmichael
  • D. E. Amundson
  • G. Seda
  • M. Daheshia
Review

Abstract

Procalcitonin (PCT) has recently emerged as a powerful biomarker for an early and accurate diagnosis of bacterial infection. Here we summarize our current understanding of the expression pathways of PCT, its potential cellular sources including immune cells, and factors inducing its secretion. Also addressed is the significance of increased blood PCT concentration, which may allow this molecule not only to act as a clinical biomarker but also as an active participant in the development and progression of infectious processes. Experimental approaches to delineate a better understanding of PCT functions, molecular pathways that modulate its expression and therapeutic opportunities to curtail its biological actions are discussed, as well.

Keywords

Procalcitonin Biomarker Inflammation Regulation Infection 

References

  1. 1.
    Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet. 1993;341(8844):515–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Fioretto JR, Martin JG, Kurokawa CS, Carpi MF, Bonatto RC, de Moraes MA, Ricchetti SM. Comparison between procalcitonin and C-reactive protein for early diagnosis of children with sepsis or septic shock. Inflamm Res. 2010;59(8):581–6.PubMedCrossRefGoogle Scholar
  3. 3.
    Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis. 2004;39(2):206–17.PubMedCrossRefGoogle Scholar
  4. 4.
    Gendrel D, Bohuon C. Procalcitonin in pediatrics for differentiation of bacterial and viral infections. Intensive Care Med. 2000;26(Suppl 2):S178–81.PubMedGoogle Scholar
  5. 5.
    Meynaar IA, Droog W, Batstra M, Vreede R, Herbrink P. In critically ill patients, serum procalcitonin is more useful in differentiating between sepsis and SIRS than CRP, Il-6, or LBP. Crit Care Res Pract. 2011;2011:594645.PubMedGoogle Scholar
  6. 6.
    Lai CC, Tan CK, Chen SY, Wang CY, Liu WL, Hou CC, Hsueh PR. Diagnostic performance of procalcitonin for bacteremia in patients with bacterial infection at the emergency department. J Infect. 2010;61(6):512–5.PubMedCrossRefGoogle Scholar
  7. 7.
    Galetto-Lacour A, Zamora SA, Gervaix A. Bedside procalcitonin and C-reactive protein tests in children with fever without localizing signs of infection seen in a referral center. Pediatrics. 2003;112(5):1054–60.PubMedCrossRefGoogle Scholar
  8. 8.
    Kim MH, Lim G, Kang SY, Lee WI, Suh JT, Lee HJ. Utility of procalcitonin as an early diagnostic marker of bacteremia in patients with acute fever. Yonsei Med J. 2011;52(2):276–81.PubMedCrossRefGoogle Scholar
  9. 9.
    Wunder C, Eichelbrönner O, Roewer N. Are IL-6, IL-10 and PCT plasma concentrations reliable for outcome prediction in severe sepsis? A comparison with APACHE III and SAPS II. Inflamm Res. 2004;53(4):158–63.PubMedCrossRefGoogle Scholar
  10. 10.
    Nylén ES, Snider RH Jr, Thompson KA, Rohatgi P, Becker KL. Pneumonitis-associated hyperprocalcitoninemia. Am J Med Sci. 1996;312(1):12–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Georgopoulou AP, Savva A, Giamarellos-Bourboulis EJ, Georgitsi M, Raftogiannis M, Antonakos N. Early changes of procalcitonin may advise about prognosis and appropriateness of antimicrobial therapy in sepsis. J Crit Care. 2011;26(3):331.e1–7.CrossRefGoogle Scholar
  12. 12.
    Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, Neidert S, Fricker T, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009;302(10):1059–66.PubMedCrossRefGoogle Scholar
  13. 13.
    Becker KL, Snider R, Nylén ES. Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target. Br J Pharmacol. 2010;159(2):253–64.PubMedCrossRefGoogle Scholar
  14. 14.
    Russwurm S, Wiederhold M, Oberhoffer M, Stonans I, Zipfel PF, Reinhart K. Molecular aspects and natural source of procalcitonin. Clin Chem Lab Med. 1999;37(8):789–97.PubMedCrossRefGoogle Scholar
  15. 15.
    Zaidi M, Moonga BS, Bevis PJ, Bascal ZA, Breimer LH. The calcitonin gene peptides: biology and clinical relevance. Crit Rev Clin Lab Sci. 1990;28(2):109–74.PubMedCrossRefGoogle Scholar
  16. 16.
    Peleg S, Abruzzese RV, Cote GJ, Gagel RF. Transcription of the human calcitonin gene is mediated by a C cell-specific enhancer containing E-box-like elements. Mol Endocrinol. 1990;4(11):1750–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Peleg S. Modified binding of proteins from calcitonin-negative tumor cells to the neuroendocrine-specific CANNTG motif of the calcitonin gene. Nucleic Acids Res. 1993;21(23):5360–5.PubMedCrossRefGoogle Scholar
  18. 18.
    Monla YT, Peleg S, Gagel RF, Monia YT. Cell type-specific regulation of transcription by cyclic adenosine 3′,5′-monophosphate-responsive elements within the calcitonin promoter. Mol Endocrinol. 1995;9(7):784–93.PubMedCrossRefGoogle Scholar
  19. 19.
    Snider RH Jr, Nylen ES, Becker KL. Procalcitonin and its component peptides in systemic inflammation: immunochemical characterization. J Investig Med. 1997;45(9):552–60.PubMedGoogle Scholar
  20. 20.
    Bolko P, Manuszewska-Jopek E, Michałek K, Waśko R, Jaskuła M, Sowiński J. Efficacy of procalcitonin measurement in patients after total thyroidectomy due to medullary thyroid carcinoma. Arch Immunol Ther Exp (Warsz). 2003;51(6):415–9.Google Scholar
  21. 21.
    Nishikura T. Procalcitonin (PCT) production in a thyroidectomized patient. Intensive Care Med. 1999;25(9):1031.PubMedCrossRefGoogle Scholar
  22. 22.
    Morgenthaler NG, Struck J, Chancerelle Y, Weglöhner W, Agay D, Bohuon C, Suarez-Domenech V, Bergmann A, Müller B. Production of procalcitonin (PCT) in non-thyroidal tissue after LPS injection. Horm Metab Res. 2003;35(5):290–5.PubMedCrossRefGoogle Scholar
  23. 23.
    Domenech VS, Nylen ES, White JC, Snider RH, Becker KL, Landmann R, Müller B. Calcitonin gene-related peptide expression in sepsis: postulation of microbial infection-specific response elements within the calcitonin I gene promoter. J Investig Med. 2001;49(6):514–21.PubMedCrossRefGoogle Scholar
  24. 24.
    Müller B, White JC, Nylén ES, Snider RH, Becker KL, Habener JF. Ubiquitous expression of the calcitonin-1 gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab. 2001;86(1):396–404.PubMedCrossRefGoogle Scholar
  25. 25.
    Giunti M, Peli A, Battilani M, Zacchini S, Militerno G, Otto CM. Evaluation of CALC-I gene (CALCA) expression in tissues of dogs with signs of the systemic inflammatory response syndrome. J Vet Emerg Crit Care (San Antonio). 2010;20(5):523–7.CrossRefGoogle Scholar
  26. 26.
    Meisner M, Müller V, Khakpour Z, Toegel E, Redl H. Induction of procalcitonin and proinflammatory cytokines in an anhepatic baboon endotoxin shock model. Shock. 2003;19(2):187–90.PubMedCrossRefGoogle Scholar
  27. 27.
    Silomon M, Bach F, Ecker D, Graeter T, Grundmann U, Larsen R. Procalcitonin after extracorporeal circulation. Synthesis in the hepatosplanchnic region. Anaesthesist. 1999;48(6):395–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Kretzschmar M, Krüger A, Schirrmeister W. Procalcitonin following elective partial liver resection—origin from the liver? Acta Anaesthesiol Scand. 2001;45(9):1162–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Oberhoffer M, Stonans I, Russwurm S, Stonane E, Vogelsang H, Junker U, et al. Procalcitonin expression in human peripheral blood mononuclear cells and its modulation by lipopolysaccharides and sepsis-related cytokines in vitro. J Lab Clin Med. 1999;134(1):49–55.PubMedCrossRefGoogle Scholar
  30. 30.
    Herget-Rosenthal S, Klein T, Marggraf G, Hirsch T, Jakob HG, Philipp T, Kribben A. Modulation and source of procalcitonin in reduced renal function and renal replacement therapy. Scand J Immunol. 2005;61(2):180–6.PubMedCrossRefGoogle Scholar
  31. 31.
    Kuzi S, Aroch I, Peleg K, Karnieli O, Klement E, Dank G. Canine procalcitonin messenger RNA expression. J Vet Diagn Invest. 2008;20(5):629–33.PubMedCrossRefGoogle Scholar
  32. 32.
    Oberhoffer M, Vogelsang H, Jäger L, Reinhart K. Katacalcin and calcitonin immunoreactivity in different types of leukocytes indicate intracellular procalcitonin content. J Crit Care. 1999;14(1):29–33.PubMedCrossRefGoogle Scholar
  33. 33.
    Balog A, Ocsovszki I, Mándi Y. Flow cytometric analysis of procalcitonin expression in human monocytes and granulocytes. Immunol Lett. 2002;84(3):199–203.PubMedCrossRefGoogle Scholar
  34. 34.
    Monneret G, Laroche B, Bienvenu J. Procalcitonin is not produced by circulating blood cells. Infection. 1999;27(1):34–5.PubMedCrossRefGoogle Scholar
  35. 35.
    Linscheid P, Seboek D, Nylen ES, Langer I, Schlatter M, Becker KL, et al. In vitro and in vivo calcitonin I gene expression in parenchymal cells: a novel product of human adipose tissue. Endocrinology. 2003;144(12):5578–84.PubMedCrossRefGoogle Scholar
  36. 36.
    Linscheid P, Seboek D, Schaer DJ, Zulewski H, Keller U, Müller B. Expression and secretion of procalcitonin and calcitonin gene-related peptide by adherent monocytes and by macrophage-activated adipocytes. Crit Care Med. 2004;32(8):1715–21.PubMedCrossRefGoogle Scholar
  37. 37.
    Koivula I, Hämäläinen S, Jantunen E, Pulkki K, Kuittinen T, Nousiainen T, et al. Elevated procalcitonin predicts Gram-negative sepsis in haematological patients with febrile neutropenia. Scand J Infect Dis. 2011;43(6–7):471–8.PubMedCrossRefGoogle Scholar
  38. 38.
    Hatzistilianou M, Rekliti A, Athanassiadou F, Catriu D. Procalcitonin as an early marker of bacterial infection in neutropenic febrile children with acute lymphoblastic leukemia. Inflamm Res. 2010;59(5):339–47.PubMedCrossRefGoogle Scholar
  39. 39.
    Miedema KG, de Bont ES, Elferink RF, van Vliet MJ, Nijhuis CS, Kamps WA, et al. The diagnostic value of CRP, IL-8, PCT, and sTREM-1 in the detection of bacterial infections in pediatric oncology patients with febrile neutropenia. Support Care Cancer. 2010. [Epub ahead of print].Google Scholar
  40. 40.
    Hatzistilianou M, Rekleity A, Athanassiadou F, DeLutiis MA, Conti P, Catriu D. Serial procalcitonin responses in infection of children with secondary immunodeficiency. Clin Invest Med. 2007;30(2):E75–85.PubMedGoogle Scholar
  41. 41.
    Axer H, Wohlfarth M, Meisner M, Finn S, Ragoschke-Schumm A, Mentzel HJ, et al. Procalcitonin as a marker for severe sepsis in an immunosuppressed patient. Anasthesiol Intensivmed Notfallmed Schmerzther. 2005;40(2):97–102.PubMedCrossRefGoogle Scholar
  42. 42.
    Al-Nawas B, Shah PM. Procalcitonin in patients with and without immunosuppression and sepsis. Infection. 1996;24(6):434–6.PubMedCrossRefGoogle Scholar
  43. 43.
    Picariello C, Lazzeri C, Valente S, Chiostri M, Attanà P, Gensini GF. Kinetics of procalcitonin in cardiogenic shock and in septic shock. Preliminary data. Acute Card Care. 2010;12(3):96–101.PubMedCrossRefGoogle Scholar
  44. 44.
    Clodi M, Vila G, Geyeregger R, Riedl M, Stulnig TM, Struck J, Luger TA, et al. Oxytocin alleviates the neuroendocrine and cytokine response to bacterial endotoxin in healthy men. Am J Physiol Endocrinol Metab. 2008;295(3):E686–91.PubMedCrossRefGoogle Scholar
  45. 45.
    Preas HL 2nd, Nylen ES, Snider RH, Becker KL, White JC, Agosti JM, et al. Effects of anti-inflammatory agents on serum levels of calcitonin precursors during human experimental endotoxemia. J Infect Dis. 2001;184(3):373–6.PubMedCrossRefGoogle Scholar
  46. 46.
    Dandona P, Nix D, Wilson MF, Aljada A, Love J, Assicot M, et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab. 1994;79(6):1605–8.PubMedCrossRefGoogle Scholar
  47. 47.
    Charles PE, Ladoire S, Aho S, Quenot JP, Doise JM, Prin S, et al. Serum procalcitonin elevation in critically ill patients at the onset of bacteremia caused by either Gram negative or Gram positive bacteria. BMC Infect Dis. 2008;26(8):38.CrossRefGoogle Scholar
  48. 48.
    Kim KE, Han JY. Evaluation of the clinical performance of an automated procalcitonin assay for the quantitative detection of bloodstream infection. Korean J Lab Med. 2010;30(2):153–9.PubMedCrossRefGoogle Scholar
  49. 49.
    von Lilienfeld-Toal M, Dietrich MP, Glasmacher A, Lehmann L, Breig P, Hahn C, et al. Markers of bacteremia in febrile neutropenic patients with hematological malignancies: procalcitonin and IL-6 are more reliable than C-reactive protein. Eur J Clin Microbiol Infect Dis. 2004;23(7):539–44.CrossRefGoogle Scholar
  50. 50.
    Nijsten MW, Olinga P, The TH, de Vries EG, Koops HS, Groothuis GM, et al. Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro. Crit Care Med. 2000;28(2):458–61.PubMedCrossRefGoogle Scholar
  51. 51.
    Kettelhack C, Hohenberger P, Schulze G, Kilpert B, Schlag PM. Induction of systemic serum procalcitonin and cardiocirculatory reactions after isolated limb perfusion with recombinant human tumor necrosis factor-alpha and melphalan. Crit Care Med. 2000;28(4):1040–6.PubMedCrossRefGoogle Scholar
  52. 52.
    Whang KT, Vath SD, Becker KL, Snider RH, Nylen ES, Muller B, et al. Procalcitonin and proinflammatory cytokine interactions in sepsis. Shock. 2000;14(1):73–8.PubMedCrossRefGoogle Scholar
  53. 53.
    Papassotiriou I, Alexiou VG, Tsironi M, Skenderi K, Spanos A, Falagas ME. Severe aseptic inflammation caused by long distance running (246 km) does not increase procalcitonin. Eur J Clin Invest. 2008;38(4):276–9.PubMedCrossRefGoogle Scholar
  54. 54.
    Chakrabartty S, Apong S. Procalcitonin estimation in Kawasaki disease. Indian Pediatr. 2009;46(7):648.PubMedGoogle Scholar
  55. 55.
    Barati M, Alinejad F, Bahar MA, Tabrisi MS, Shamshiri AR, Bodouhi NO, Karimi H. Comparison of WBC, ESR, CRP and PCT serum levels in septic and non-septic burn cases. Burns. 2008;34(6):770–4.PubMedCrossRefGoogle Scholar
  56. 56.
    Latour-Pérez J, Alcalá-López A, García-García MA, Sánchez-Hernández JF, Abad-Terrado C, Viedma-Contreras JA, et al. Diagnostic accuracy of sTREM-1 to identify infection in critically ill patients with systemic inflammatory response syndrome. Clin Biochem. 2010;43(9):720–4.PubMedCrossRefGoogle Scholar
  57. 57.
    Dahaba AA, Hagara B, Fall A, Rehak PH, List WF, Metzler H. Procalcitonin for early prediction of survival outcome in postoperative critically ill patients with severe sepsis. Br J Anaesth. 2006;97(4):503–8.PubMedCrossRefGoogle Scholar
  58. 58.
    Harbarth S, Holeckova K, Froidevaux C, Pittet D, Ricou B, Grau GE, et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med. 2001;164(3):396–402.PubMedGoogle Scholar
  59. 59.
    Steinwald PM, Whang KT, Becker KL, Snider RH, Nylen ES, White JC. Elevated calcitonin precursor levels are related to mortality in an animal model of sepsis. Crit Care. 1999;3(1):11–6.PubMedCrossRefGoogle Scholar
  60. 60.
    Nylen ES, Whang KT, Snider RH Jr, Steinwald PM, White JC, Becker KL. Mortality is increased by procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis. Crit Care Med. 1998;26(6):1001–6.PubMedCrossRefGoogle Scholar
  61. 61.
    Wagner KE, Martinez JM, Vath SD, Snider RH, Nylén ES, Becker KL, et al. Early immunoneutralization of calcitonin precursors attenuates the adverse physiologic response to sepsis in pigs. Crit Care Med. 2002;30(10):2313–21.PubMedCrossRefGoogle Scholar
  62. 62.
    Tavares E, Miñano FJ. Immunoneutralization of the aminoprocalcitonin peptide of procalcitonin protects rats from lethal endotoxaemia: neuroendocrine and systemic studies. Clin Sci (Lond). 2010;119(12):519–34.CrossRefGoogle Scholar
  63. 63.
    Martinez JM, Wagner KE, Snider RH, Nylen ES, Muller B, Sarani B. Late immunoneutralization of procalcitonin arrests the progression of lethal porcine sepsis. Surg Infect (Larchmt). 2001;2(3):193–202. discussion 202–203.CrossRefGoogle Scholar
  64. 64.
    Liappis AP, Gibbs KW, Nylen ES, Yoon B, Snider RH, Gao B, et al. Exogenous procalcitonin evokes a pro-inflammatory cytokine response. Inflamm Res. 2011;60(2):203–7.PubMedCrossRefGoogle Scholar
  65. 65.
    Wei JX, Verity A, Garle M, Mahajan R, Wilson V. Examination of the effect of procalcitonin on human leucocytes and the porcine isolated coronary artery. Br J Anaesth. 2008;100(5):612–21.PubMedCrossRefGoogle Scholar
  66. 66.
    Wiedermann FJ, Kaneider N, Egger P, Tiefenthaler W, Wiedermann CJ, Lindner KH, et al. Migration of human monocytes in response to procalcitonin. Crit Care Med. 2002;30(5):1112–7.PubMedCrossRefGoogle Scholar
  67. 67.
    Serezani CH, Ballinger MN, Aronoff DM, Peters-Golden M. Cyclic AMP: master regulator of innate immune cell function. Am J Respir Cell Mol Biol. 2008;39(2):127–32.PubMedCrossRefGoogle Scholar
  68. 68.
    Pincíková T, Bucová M, Slobodníková L. Influence of recombinant human procalcitonin on phagocytic and candidacidal ability of polymorphonuclear leukocytes and on killing mechanisms of serum and blood against bacteria Staphylococcus aureus and Escherichia coli. Vnitr Lek. 2005;51(12):1365–70.PubMedGoogle Scholar
  69. 69.
    Monneret G, Pachot A, Laroche B, Picollet J, Bienvenu J. Procalcitonin and calcitonin gene-related peptide decrease LPS-induced tnf production by human circulating blood cells. Cytokine. 2000;12(6):762–4.PubMedCrossRefGoogle Scholar
  70. 70.
    Bucova M, Zahorec R, Buc M. Immunomodulatory effect of recombinant human procalcitonin on mitogenic activity of lymphocytes. Cent Eur J Immunol. 2006;31:87–93.Google Scholar
  71. 71.
    Hoffmann G, Schobersberger W. Anti-inflammatory procalcitonin (PTC) in a human whole blood model septic shock. Cytokine. 2000;12(6):762–4.CrossRefGoogle Scholar
  72. 72.
    Hoffmann G, Totzke G, Seibel M, Smolny M, Wiedermann FJ, Schobersberger W. In vitro modulation of inducible nitric oxide synthase gene expression and nitric oxide synthesis by procalcitonin. Crit Care Med. 2001;29(1):112–6.PubMedCrossRefGoogle Scholar
  73. 73.
    Hoffmann G, Czechowski M, Schloesser M, Schobersberger W. Procalcitonin amplifies inducible nitric oxide synthase gene expression and nitric oxide production in vascular smooth muscle cells. Crit Care Med. 2002;30(9):2091–5.PubMedCrossRefGoogle Scholar
  74. 74.
    Abbasi A, Corpeleijn E, Postmus D, Gansevoort RT, de Jong PE, Gans RO, et al. Plasma procalcitonin and risk of type 2 diabetes in the general population. Diabetologia. 2011. [Epub ahead of print].Google Scholar
  75. 75.
    Jereb M, Lunaček NK, Kotar T, Saksida A, Petrovec M, Avšič-Županc T. Procalcitonin in hantavirus infections. Scand J Clin Lab Invest. 2011;71(4):287–91.PubMedCrossRefGoogle Scholar
  76. 76.
    Christ-Crain M, Müller B. Procalcitonin and pneumonia: is it a useful marker? Curr Infect Dis Rep. 2007;9(3):233–40.PubMedCrossRefGoogle Scholar
  77. 77.
    Becker KL, Bivins LE, Radfar RH, Snider RH, Moore CF, Silva OL. Study of calcitonin heterogeneity using a radioreceptor assay. Horm Metab Res. 1978;10(5):457–8.PubMedCrossRefGoogle Scholar
  78. 78.
    Jullienne A, Raulais D, Calmettes C, Moukhtar MS, Milhaud G. Heterogeneity of immunoreactive calcitonin in normal human thyroid. Horm Metab Res. 1978;10(5):456–7.PubMedCrossRefGoogle Scholar
  79. 79.
    Sexton PM, Christopoulos G, Christopoulos A, Nylen ES, Snider RH Jr, Becker KL. Procalcitonin has bioactivity at calcitonin receptor family complexes: potential mediator implications in sepsis. Crit Care Med. 2008;36(5):1637–40.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Basel AG 2012

Authors and Affiliations

  • G. N. Matwiyoff
    • 1
  • J. D. Prahl
    • 1
  • R. J. Miller
    • 1
  • J. J. Carmichael
    • 1
  • D. E. Amundson
    • 2
  • G. Seda
    • 1
  • M. Daheshia
    • 1
  1. 1.Department of Pulmonary MedicineNaval Medical Center San DiegoSan DiegoUSA
  2. 2.Department of Critical CareScripps Memorial HospitalEncinitasUSA

Personalised recommendations